{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:09:29Z","timestamp":1769126969114,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.aace.2020.11.019","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:00:50Z","timestamp":1609423250000},"page":"10-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors"],"prefix":"10.1016","volume":"7","author":[{"given":"Rebecca J.","family":"Vitale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis K.","family":"Valtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie E.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine E.","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi D.L.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.aace.2020.11.019_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.aace.2020.11.019_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dsx.2020.04.004","article-title":"Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"10.1016\/j.aace.2020.11.019_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4093\/dmj.2020.0091","article-title":"Acute hyperglycemic crises with coronavirus disease-19: case reports","volume":"44","author":"Kim","year":"2020","journal-title":"Diabetes Metab J"},{"issue":"2","key":"10.1016\/j.aace.2020.11.019_bib4","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.dsx.2019.03.022","article-title":"DKA cases over the last three years: has anything changed?","volume":"13","author":"Stratigou","year":"2019","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"10.1016\/j.aace.2020.11.019_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00592-009-0109-4","article-title":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes","volume":"47","author":"Yang","year":"2010","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.aace.2020.11.019_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.aace.2020.11.019_bib7","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"22","key":"10.1016\/j.aace.2020.11.019_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.aace.2020.11.019_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2019.12.004","article-title":"Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction\u2014The EMMY trial","volume":"221","author":"Tripolt","year":"2020","journal-title":"Am Heart J"},{"issue":"5866","key":"10.1016\/j.aace.2020.11.019_bib12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro","year":"1973","journal-title":"Br Med J"},{"issue":"9","key":"10.1016\/j.aace.2020.11.019_bib13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium\u2013glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.aace.2020.11.019_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40261-019-00794-5","article-title":"Adverse drug reaction profile of SGLT2 inhibitor-associated diabetic ketosis\/ketoacidosis in Singapore and their precipitating factors","volume":"39","author":"Limenta","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.aace.2020.11.019_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11892-016-0721-y","article-title":"Stress hyperglycemia during surgery and anesthesia: pathogenesis and clinical implications","volume":"16","author":"Palermo","year":"2016","journal-title":"Curr Diab Rep"},{"issue":"8","key":"10.1016\/j.aace.2020.11.019_bib16","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1210\/clinem\/dgaa360","article-title":"Diabetic ketoacidosis in COVID-19: unique concerns and considerations","volume":"105","author":"Palermo","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.aace.2020.11.019_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMc2018688","article-title":"New-onset diabetes in Covid-19","volume":"383","author":"Rubino","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.aace.2020.11.019_bib18","first-page":"607","article-title":"The pathogenesis and treatment of the \u2018cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J\u00a0Infect"},{"issue":"8","key":"10.1016\/j.aace.2020.11.019_bib19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2337\/diabetes.53.8.2079","article-title":"Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises","volume":"53","author":"Stentz","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.aace.2020.11.019_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.117","article-title":"Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy","volume":"3","author":"Westcott","year":"2020","journal-title":"Endocrinol Diabetes Metab"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520310208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520310208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:31:56Z","timestamp":1762497116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060520310208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2376060520310208"],"URL":"https:\/\/doi.org\/10.1016\/j.aace.2020.11.019","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aace.2020.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}